SALL4 and its clinical application value in nongerm cell tumors

Abstract

CHEN Yuan-Yuan, YE Yuan-Yuan, XU Feng, LI Zhi-Zhen, LIU Ying-Bin, HAN Bao-San. SALL4 and its clinical application value in nongerm cell tumors[J]. Journal of International Oncology, 2016, 43(2): 155-.

References

1］ Tanimura N, Saito M, Ebisuya M, et al. Stemnessrelated factor Sall4 interacts with transcription factors Oct3/4 and Sox2 and occupies OctSox elements in mouse embryonic stem cells［J］. J Biol Chem, 2013, 288(7): 50275038. DOI:10.1074/jbc.M112.411173. ［2］ Yong KJ, Gao C, Lim JS, et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma［J］. N Engl J Med, 2013, 368(24): 22662276. DOI:10.1056/NEJMoa1300297. ［3］ Zhang L, Yan Y, Jiang Y, et al. The expression of SALL4 in patients with gliomas: high level of SALL4 expression is correlated with poor outcome［J］. J Neurooncol, 2015, 121(2): 261268. DOI:10.1007/s1106001416464. ［4］ Han SX, Wang JL, Guo XJ, et al. Serum SALL4 is a novel prognosis biomarker with tumor recurrence and poor survival of patients in hepatocellular carcinoma［J］. J Immunol Res, 2014, 2014: 262385. DOI:10.1155/2014/262385. ［5］ Zeng SS, Yamashita T, Kondo M, et al. The transcription factor SALL4 regulates stemness of EpCAMpositive hepatocellular carcinoma［J］. J Hepatol, 2014, 60(1): 127134. DOI:10.1016/j.jhep.2013.08.024. ［6］ Forghanifard MM, Ardalan Khales S, JavdaniMallak A, et al. Stemness state regulators SALL4 and SOX2 are involved in progression and invasiveness of esophageal squamous cell carcinoma［J］. Med Oncol, 2014, 31(4): 922. DOI:10.1007/s1203201409227. ［7］ Cao D, Humphrey PA, Allan RW. SALL4 is a novel sensitive and specific marker for metastatic germ cell tumors, with particular utility in detection of metastatic yolk sac tumors［J］. Cancer, 2009, 115(12): 26402651. DOI:10.1002/cncr.24308. ［8］ Vasiljevic A, Szathmari A, Champier J, et al. Histopathology of pineal germ cell tumors［J］. Neurochirurgie, 2015, 61(2/3): 130137. DOI:10.1016/j.neuchi.2013.06.006. ［9］ Trinh DT, Shibata K, Hirosawa T, et al. Diagnostic utility of CD117, CD133, SALL4, OCT4, TCL1 and glypican3 in malignant germ cell tumors of the ovary［J］. J Obstet Gynaecol Res, 2012, 38(5): 841848. DOI:10.1111/j.14470756.2011.01798.x. ［10］ Bai S, Wei S, Ziober A, et al. SALL4 and SF1 are sensitive and specific markers for distinguishing granulosa cell tumors from yolk sac tumors［J］. Int J Surg Pathol, 2013, 21(2): 121125. DOI:10.1177/1066896912454567. ［11］ Cao D, Li J, Guo CC, et al. SALL4 is a novel diagnostic marker for testicular germ cell tumors［J］. Am J Surg Pathol, 2009, 33(7): 10651077. DOI:10.1097/PAS.0b013e3181a13eef. ［12］ Camparo P, Comperat EM. SALL4 is a useful marker in the diagnostic workup of germ cell tumors in extratesticular locations［J］. Virchows Arch, 2013, 462(3): 337341. DOI:10.1007/s0042801213535. ［13］ Yang F, Yao Y, Jiang Y, et al. Sumoylation is important for stability, subcellular localization, and transcriptional activity of SALL4, an essential stem cell transcription factor［J］. J Biol Chem, 2012, 287(46): 3860038608. DOI:10.1074/jbc.M112.391441. ［14］ Yang J, Corsello TR, Ma Y. Stem cell gene SALL4 suppresses transcription through recruitment of DNA methyltransferases［J］. J Biol Chem, 2012, 287(3): 19962005. DOI:10.1074/jbc.M111.308734. ［15］ Rao S, Zhen S, Roumiantsev S, et al. Differential roles of Sall4 isoforms in embryonic stem cell pluripotency［J］. Mol Cell Biol, 2010, 30(22): 53645380. DOI:10.1128/MCB.0041910. ［16］ Ardalan Khales S, Abbaszadegan MR, Abdollahi A, et al. SALL4 as a new biomarker for early colorectal cancers［J］. J Cancer Res Clin Oncol, 2015, 141(2): 229235. DOI:10.1007/s004320141808y. ［17］ Forghanifard MM, Moghbeli M, Raeisossadati R, et al. Role of SALL4 in the progression and metastasis of colorectal cancer［J］. J Biomed Sci, 2013, 20: 6. DOI:10.1186/14230127206. ［18］ Kobayashi D, Kuribayashi K, Tanaka M, et al. Overexpression of SALL4 in lung cancer and its importance in cell proliferation［J］. Oncol Rep, 2011, 26(4): 965970. DOI:10.3892/or.2011.1374. ［19］ Kobayashi D, Kuribayshi K, Tanaka M, et al. SALL4 is essential for cancer cell proliferation and is overexpressed at early clinical stages in breast cancer［J］. Int J Oncol, 2011, 38(4): 933939. DOI:10.3892/ijo.2011.929. ［20］ Deisch J, Raisanen J, Rakheja D. Immunohistochemical expression of embryonic stem cell markers in malignant rhabdoid tumors［J］. Pediatr Dev Pathol, 2011, 14(5): 353359. DOI:10.2350/10090902OA.1. ［21］ Venneti S, Le P, Martinez D, et al. Malignant rhabdoid tumors Express stem cell factors, which Relate to the expression of EZH2 and Id proteins［J］. Am J Surg Pathol, 2011, 35(10): 14631472. DOI:10.1097/PAS.0b013e318224d2cd. ［22］ Yoshida A, Asano N, Kawai A, et al. Differential SALL4 immunoexpression in malignant rhabdoid tumours and epithelioid sarcomas［J］. Histopathology, 2015, 66(2): 252261. DOI:10.1111/his.12460. ［23］ Ushiku T, Shinozaki A, Shibahara J, et al. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma［J］. Am J Surg Pathol, 2010, 34(4): 533540. DOI:10.1097/PAS.0b013e3181d1dcdd. ［24］ Ikeda H, Sato Y, Yoneda N, et al. αFetoproteinproducing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression［J］. Hum Pathol, 2012, 43(11): 19551963. DOI:10.1016/j.humpath.2011.11.022. ［25］ Oikawa T, Kamiya A, Zeniya M, et al. Sallike protein 4 (SALL4), a stem cell biomarker in liver cancers［J］. Hepatology, 2013, 57(4): 14691483. DOI:10.1002/hep.26159. ［26］ GonzalezRoibon N, Katz B, Chaux A, et al. Immunohistochemical expression of SALL4 in hepatocellular carcinoma, a potential pitfall in the differential diagnosis of yolk sac tumors［J］. Hum Pathol, 2013, 44(7): 12931299. DOI:10.1016/j.humpath.2012.10.017. ［27］ Liu TC, Vachharajani N, Chapman WC, et al. SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases［J］. Am J Surg Pathol, 2014, 38(7): 966972. DOI:10.1097/PAS.0000000000000218. ［28］ Momenzadeh D, Rahmanzadeh S, RezaeiTavirani M, et al. ZNF797 plays an oncogenic role in gastric cancer［J］. Genet Mol Res, 2014, 13(4): 84218427. DOI:10.4238/2014.October.20.18. ［29］ Jeong HW, Cui W, Yang Y, et al. SALL4, a stem cell factor, affects the side population by regulation of the ATPbinding cassette drug transport genes［J］. PLoS One, 2011, 6(4): e18372. DOI:10.1371/journal.pone.0018372. ［30］ Yanagihara N, Kobayashi D, Kuribayashi K, et al. Significance of SALL4 as a drug?resistant factor in lung cancer［J］. Int J Oncol, 2015, 46(4): 15271534. DOI:10.3892/ijo.2015.2866.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.